Business Context and Reporting Period
Company: Scilex Holding Company (Parent of Semnur Pharmaceuticals, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: September 3, 2024
Event Date: August 30, 2024
Primary Event: Entry into a Material Definitive Agreement (Merger Agreement) with Denali Capital Acquisition Corp. ("Denali").
On August 30, 2024, Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex, entered into an agreement to merge with Denali Merger Sub Inc. Upon closing, Denali will domesticate as a Delaware corporation, change its name to "Semnur Pharmaceuticals, Inc.," and the combined entity will be listed on The Nasdaq Stock Market LLC. The transaction is expected to close in the first quarter of 2025.
Key Financial Metrics and Transaction Terms
- Equity Valuation: Semnur's equity value is set at $2,500,000,000 for the purposes of the Merger Agreement.
- Debt Restructuring: Scilex agreed to contribute outstanding indebtedness owed by Semnur (approximately $37,228,589 as of June 30, 2024, capped at $60,000,000) in exchange for Series A Preferred Stock of Semnur. This debt will be extinguished upon the contribution.
- Sponsor Interest Purchase: Scilex agreed to purchase 500,000 Class B ordinary shares of Denali from the Sponsor for $2,000,000 in cash and 300,000 shares of Scilex common stock (to be issued post-closing).
- Warrant Adjustments: Oramed Pharmaceuticals, Inc. warrants to purchase up to 10,875,000 shares of Scilex common stock were fully vested as of the agreement date, with immediate exercisability granted for up to 5,437,500 shares.
Note: This filing does not provide standard operating financial metrics such as revenue, net income, operating cash flow, or liquidity ratios for the reporting period.
Material Changes and Conditions
The filing details a material change in corporate structure via a proposed business combination. Key conditions to closing include:
- Shareholder Approval: Requisite approval from Denali's shareholders and written consent from Semnur's stockholders (Scilex).
- Debt Resolution: Scilex must either pay in full or obtain a release from Semnur as a guarantor for the Senior Secured Promissory Note owed to Oramed Pharmaceuticals, Inc.
- Regulatory and Listing: Expiration of the HSR Act waiting period, effectiveness of the SEC registration statement, and continued listing of securities on Nasdaq.
- Financial Deliverables: Semnur must deliver audited financial statements for fiscal years 2022 and 2023 by September 13, 2024.
Outlook, Risks, and Management Commentary
Outlook: The Business Combination is anticipated to close during the first quarter of 2025. Post-closing, Scilex will hold New Semnur Preferred Shares, granting it the right to designate directors to the board of the combined company.
Risks and Contingencies:
- Termination Risks: The agreement may be terminated if not consummated by January 31, 2025 (the "Outside Date"), if shareholder approval is not obtained, or if material adverse effects occur.
- Redemption Risk: The transaction is subject to the amount of redemption requests made by Denali's shareholders.
- Integration and Operations: Risks include the inability to realize anticipated benefits, disruption of current plans, and difficulty integrating businesses.
- Forward-Looking Statements: Management explicitly disclaims any obligation to update forward-looking statements, noting that actual results may differ materially due to economic conditions and other uncertainties.
Investor Verification Checklist
- Verify the status of the Senior Secured Promissory Note owed to Oramed Pharmaceuticals, Inc., as its resolution is a condition to closing.
- Confirm the delivery of Semnur's audited financial statements for 2022 and 2023 by the September 13, 2024 deadline.
- Monitor the Denali Registration Statement (Form S-4) for the definitive proxy statement/prospectus regarding shareholder voting.
- Review the terms of the Oramed Warrants, specifically the immediate exercisability of 5,437,500 shares, to assess potential dilution.
- Track the "Outside Date" of January 31, 2025, for potential termination of the merger agreement.